<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04060342</url>
  </required_header>
  <id_info>
    <org_study_id>GB1275-1101 (KEYNOTE-A36)</org_study_id>
    <nct_id>NCT04060342</nct_id>
  </id_info>
  <brief_title>GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma</brief_title>
  <official_title>A Phase 1/2, First-in-Human, Open-label, Dose Escalation Study of GB1275 Monotherapy and in Combination With an Anti-PD-1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma, Followed by Basket Expansion of GB1275 With Standard of Care or in Combination With an Anti-PD-1 Antibody in Patients With Specified Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MSD International GmbH (Merck Sharp &amp; Dohme Corp, a subsidiary of Merck &amp; Co., Inc.)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gossamer Bio Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase
      1 Dose Escalation phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in
      combination with Standard of Care in Patients with Metastatic Pancreatic Adenocarcinoma
      followed by a Phase 2 Basket Expansion phase in Patients with Specified Metastatic Solid
      Tumors
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2019</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Phase 1 - Dose Escalation of 3 different Regimen Phase 2 - Dose Expansion of 3 Cohorts</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 - Regimens A, B,and C: Incidence of dose limiting toxicities (DLTs)</measure>
    <time_frame>Regimen A and B dose escalation Days 1-21, Regimen C dose escalations Days 1-36 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 - Regimens A, B,and C: Incidence of adverse events (AEs)</measure>
    <time_frame>Regimen A, B, and C dose escalation from baseline through 30 days last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 - Regimens A and B: Cmax of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 - Regimens A and B: Ctrough of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Trough observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 - Regimens A and B: Tmax of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Time of maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 - Regimens A and B: t1/2 of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Terminal phase elimination half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 - Regimens A and B: AUC of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Area under the plasma concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 - Regimens A and B: CL/F of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Oral clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 - Expansion Cohorts 1, 2 and 3: Objective Response Rate (ORR)</measure>
    <time_frame>24 months</time_frame>
    <description>ORR defined as the proportion of subjects with best overall confirmed response (BOCR) of either a complete response (CR) or partial response (PR) as assessed by the Investigator based on RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - Regimen C: Cmax of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - Regimen C: Ctrough of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Trough observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - Regimen C: Tmax of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Time of maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - Regimen C: t1/2 of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Terminal phase elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - Regimen C: AUC of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Area under the plasma concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - Regimen C: CL/F of GB1275</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Oral clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - Regimen C: Cmax of nab-paclitaxel and gemcitabine</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - Regimen C: Tmax of nab-paclitaxel and gemcitabine)</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Time of maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - Regimen C: AUC of nab-paclitaxel and gemcitabine</measure>
    <time_frame>From baseline through 30 days last dose</time_frame>
    <description>Area under the plasma concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Expansion Cohorts 1, 2, and 3: Duration of Response (DOR)</measure>
    <time_frame>24 months</time_frame>
    <description>DOR defined as time from date of objective response to first documented date of disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Expansion Cohorts 1, 2, and 3: Time to Response (TTR)</measure>
    <time_frame>24 months</time_frame>
    <description>TTR defined as time from first dose to first date of objective response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Expansion Cohorts 1, 2, and 3: Clinical Benefit Rate (CBR)</measure>
    <time_frame>6 months</time_frame>
    <description>CBR defined as proportion of subjects with confirmed CR, PR, or stable disease (SD) at six months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Expansion Cohorts 1, 2, and 3: Progression Free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>PFS defined as time from first dose to first documented date of disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Expansion Cohorts 1, 2, and 3: Time to Progression (TTP)</measure>
    <time_frame>24 months</time_frame>
    <description>TTP defined as time from first dose to first documented date of disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Expansion Cohorts 1, 2, and 3: Overall Survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>OS defined as time from first dose to date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Expansion Cohorts 1, 2, and 3: Incidence of AEs</measure>
    <time_frame>Cohorts 1, 2 and 3 dose expansion from baseline through 30 days last dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Expansion Cohort 1, 2 and 3: PK profile of GB1275</measure>
    <time_frame>Cohorts 1, 2, and 3 dose expansion from baseline through 30 days last dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <condition>Esophageal Adenocarcinoma</condition>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <condition>Gastric Adenocarcinoma</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Castration-resistant Prostate Cancer</condition>
  <condition>Microsatellite Stable Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1: Regimen A - GB1275 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GB1275 Monotherapy dose escalation: Oral administration. Twice per day (BID).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Regimen B - GB1275 with an Anti-PD-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GB1275 with pembrolizumab dose escalation:
GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Regimen C - GB1275 with Standard of Care (SOC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GB1275 with SOC dose escalation:
GB1275 oral administration; twice per day (BID), and nab-paclitaxel and gemcitabine per United States Prescribing Information (USPI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Cohort 1 - GB1275 with SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GB1275 with SOC Cohort Expansion in patients with newly diagnosed metastatic pancreatic cancer:
GB1275 oral administration; twice per day (BID) and nab-paclitaxel and gemcitabine per USPI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Cohort 2 - GB1275 with an Anti-PD-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GB1275 with pembrolizumab Cohort Expansion in patients with MSS colorectal cancer:
GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Cohort 3 - GB1275 with an Anti-PD-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GB1275 with pembrolizumab Cohort Expansion in patients with gastric/GEJ cancer, PD-L1 positive:
GB1275 oral administration; twice per day (BID), and pembrolizumab IV administration once every 3 weeks (Q3W).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GB1275</intervention_name>
    <description>Oral</description>
    <arm_group_label>Phase 1: Regimen A - GB1275 monotherapy</arm_group_label>
    <arm_group_label>Phase 1: Regimen B - GB1275 with an Anti-PD-1</arm_group_label>
    <arm_group_label>Phase 1: Regimen C - GB1275 with Standard of Care (SOC)</arm_group_label>
    <arm_group_label>Phase 2: Cohort 1 - GB1275 with SOC</arm_group_label>
    <arm_group_label>Phase 2: Cohort 2 - GB1275 with an Anti-PD-1</arm_group_label>
    <arm_group_label>Phase 2: Cohort 3 - GB1275 with an Anti-PD-1</arm_group_label>
    <other_name>Investigational</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel and gemcitabine</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Phase 1: Regimen C - GB1275 with Standard of Care (SOC)</arm_group_label>
    <arm_group_label>Phase 2: Cohort 1 - GB1275 with SOC</arm_group_label>
    <other_name>Abraxane and Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Phase 1: Regimen B - GB1275 with an Anti-PD-1</arm_group_label>
    <arm_group_label>Phase 2: Cohort 2 - GB1275 with an Anti-PD-1</arm_group_label>
    <arm_group_label>Phase 2: Cohort 3 - GB1275 with an Anti-PD-1</arm_group_label>
    <other_name>Anti-PD-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group
             (ECOG) Performance Scale.

          -  Women of childbearing potential must use an acceptable method of contraception

        Phase 1

        Subjects with the the following:

          -  Regimen A and B:

               -  pancreatic adenocarcinoma,

               -  esophageal adenocarcinoma, or esophageal squamous cell carcinoma, or

               -  gastric/gastroesophageal junction adenocarcinoma, or

               -  TNBC, or

               -  prostate cancer, or

               -  colorectal adenocarcinoma

          -  Regimen C: pancreatic cancer

        Phase 2

          -  Cohort 1: pancreatic cancer.

          -  Cohort 2: colorectal cancer

          -  Cohort 3: gastric/GEJ adenocarcinoma

        Exclusion Criteria:

          -  History of another malignancy within 2 years prior to first study drug(s)
             administration, unless the malignancy was treated with curative intent and the
             likelihood of relapse is &lt;5% in 2 years

          -  Pregnant or nursing

          -  Known history of testing positive for human immunodeficiency virus (HIV)

          -  Gastrointestinal (GI) tract disease causing the inability to take oral medication.

          -  Positive test for Hepatitis B virus surface antigen (HBsAg) or a and/or positive Hep C
             antibody result with detectable hepatitis C virus (HCV) ribonucleic acid (RNA)
             indicating acute or chronic infection.

        Other protocol-defined inclusion/exclusion criteria will apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.</last_name>
    <phone>1-866-668-4083</phone>
    <email>ClinicalTrials@gossamerbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Hospital, Anschutz Cancer Pavilion (ACP)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine - Siteman Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Sarah Cannon Research Institute/Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royals Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2019</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GEJ adenocarcinoma</keyword>
  <keyword>TNBC</keyword>
  <keyword>MSS mCRC</keyword>
  <keyword>PD-L1 + gastric cancer</keyword>
  <keyword>PD-L1 positive gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

